Vaccitech

Vaccitech Plc operates as a holding company. It is engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company was founded in March 2021 and is headquartered in Oxford, the United Kingdom.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Barinthus Biotherapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. It also focuses on the pipeline of both clinical and preclinical stage therapeutic, and prophylactic programs. The company was founded by Adrian Hill and Dame Sarah Gilbert in March 2021 and is headquartered in Didcot, the United Kingdom.

OXFORD, United Kingdom, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer will present data from its Phase 2 Hepatitis B trials of VTP-300 at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023, November 10-14 in Boston, MA.

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

OXFORD, United Kingdom, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced it will host a Key Opinion Leader (KOL) Webinar to discuss the current treatment landscape for people living with chronic Hepatitis B Virus (HBV) infection and potential paths to a functional cure. Details are as follows:

Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023

OXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced its financial results for the second quarter of 2023 and provided an overview of the Company's progress.

Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

OXFORD, United Kingdom, June 21, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics for the treatment of autoimmunity, chronic infectious diseases and cancer, will present positive final data from the HBV002 clinical trial at the European Association for the Study of the Liver (EASL) Congress 2023 – The International Liver CongressTM taking place June 21-24 in Vienna, Austria. HBV002 (NCT04778904) is a Phase 1b/2a clinical trial of VTP-300 in adults with chronic Hepatitis B (CHB). The data will be presented as a poster at EASL on Saturday, June 24 (Poster ID: SAT-198), by Eleanor Barnes, Professor of Hepatology and Experimental Medicine at Oxford University.

Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B

OXFORD, United Kingdom, June 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics for the treatment of autoimmunity, chronic infectious diseases and cancer, today announced the dosing of the first patient in the PCA001 clinical trial (NCT05617040). PCA001 is a multi-centre, Phase 1/2 clinical trial designed to determine the recommended Phase 2 regimen and evaluate the safety, efficacy, as measured by prostate-specific antigen (PSA) response, and T cell response of VTP-850 monotherapy in men with rising PSA after definitive local therapy for their disease (i.e., biochemical recurrence).

Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy

OXFORD, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity and cancer, today announced its financial results for the first quarter of 2023 and an overview of the Company's progress.

Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments

AbCellera Biologics

Chimerix

Kiniksa Pharmaceuticals Ltd

Ocuphire Pharma

Point Biopharma Global

Vir Biotechnology

While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, the market presence of the surprise production cuts by the Organization of the Petroleum Exporting Countries (OPEC) and non-member oil-producing nations — known as OPEC+ — along with the Federal Reserve's possible response.

7 Thrilling Biotech Stocks for Aggressive Investors to Buy

OXFORD, United Kingdom, March 28, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company focused on the development of novel T cell immunotherapeutics designed to use the power of the immune system to potentially treat and cure chronic infectious diseases, autoimmune diseases and cancer, today announced positive topline final data from the HBV002 study (NCT04778904), a Phase 1b/2a clinical trial of VTP-300 in people with chronic Hepatitis B (HBV) infection.

Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B

OXFORD, United Kingdom, March 24, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity and cancer, today announced its financial results for year end 2022 and an overview of the Company's progress.

Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments

OXFORD, United Kingdom, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced that it will host a Key Opinion Leader (KOL) webinar on its SNAPvax™ Platform and application in tolerogenic immunotherapies for celiac disease and other autoimmune diseases on Monday, November 28, 2022 at 4:30 pm ET. Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity, and cancer.

Vaccitech to Host KOL Webinar on the SNAPvax™ Platform for Inducing Tolerance to Treat Celiac and other Autoimmune Diseases

OXFORD, United Kingdom, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the third quarter ended September 30, 2022 and provided an overview of the Company's recent corporate developments. Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity, and cancer.

Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

VTP-300 induced sustained reductions of hepatitis B surface antigen in people with chronic hepatitis B during ongoing, fully enrolled Phase 1b/2a trial.

Vaccitech Provides Update on Ongoing VTP-300 Phase 1b/2a Trial Showing Sustained Reductions of HBsAg in Patients with Chronic Hepatitis B

OXFORD, United Kingdom, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company will be presenting an update on its Phase 1b/2a study of VTP-300, Vaccitech's novel immunotherapy for chronic hepatitis B, at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting®, in Washington, D.C., November 4 – 8, 2022.

Vaccitech Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® Providing Update on the Phase 1b/2a Study of VTP-300

OXFORD, United Kingdom, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Scientific Officer, Dr. Thomas G. Evans, Vice President, Corporate Development, Nick Fullenkamp, Senior Vice President, Synthetic Immunotherapies, Dr. Geoffrey Lynn, and Senior Research Development Scientist, Dr. Hugh Welles will be participating in the following conferences in October.

Vaccitech to Present at Upcoming October Investor & Scientific Conferences

OXFORD, United Kingdom, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced the promotion of Gemma Brown as Chief Financial Officer (CFO). Gemma Brown succeeds Georgy Egorov.

Vaccitech Promotes Gemma Brown as Chief Financial Officer

OXFORD, United Kingdom, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will be participating in the following investment conferences in September.

Vaccitech to Present at Upcoming September Investors Conferences

Vaccitech PLC Sponsored ADR (VACC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Vaccitech PLC Sponsored ADR (VACC) Upgraded to Buy: Here's Why

OXFORD, United Kingdom, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter ended June 30, 2022 and provided an overview of the Company's recent corporate developments. Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity, and cancer.

Vaccitech Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

OXFORD, United Kingdom, July 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Executive Officer, Bill Enright, will participate in a fireside chat at the William Blair Biotech Focus Conference 2022 in New York, July 11 to 12. Mr. Enright will also host one on one meetings with investors at the conference.

Vaccitech to Present at the William Blair Biotech Focus Conference 2022

Vaccitech plc (NASDAQ: VACC) announced an update to the interim analysis of safety and efficacy data from the HBV002 study evaluating ChAdOx1-HBV and MVA-HBV vaccines (VTP-300) in chronic HBV patients who are virally suppressed with oral anti-viral therapies. In the VTP-.

Vaccitech's Vaccine Induced Sustained Reductions In Hepatitis B Associated Antigens

VTP-300 as a monotherapy and in combination with a single administration of low-dose nivolumab was administered, with no treatment-related serious adverse events and infrequent transient transaminitis.

Vaccitech's VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1

OXFORD, United Kingdom, June 06, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will participate in a fireside chat at the Jefferies Global Healthcare Conference at 8:30 a.m. EDT on Wednesday, June 8, 2022 in New York City.

Vaccitech to Present at the Jefferies Healthcare Conference

Trial will evaluate AB-729, an RNAi therapy in combination with VTP-300, an immunotherapeutic, and NA therapy Trial will evaluate AB-729, an RNAi therapy in combination with VTP-300, an immunotherapeutic, and NA therapy

Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

OXFORD, United Kingdom, May 20, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will present at the H.C. Wainwright Global Investment Conference at 12:00 p.m. EDT on Tuesday, May 24, 2022. The conference will be held both in person in Miami and virtually.

Vaccitech to Present at the H.C. Wainwright Global Investment Conference

OXFORD, United Kingdom, May 11, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the first quarter ended March 31, 2022, and provided an overview of the Company's recent corporate developments. Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity, and cancer.

News for Vaccitech Stock (VACC)